APA citiranje

Fala, L. (2016). Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer. Am Health Drug Benefits.

Citação norma Chicago

Fala, Loretta. "Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer." Am Health Drug Benefits 2016.

MLA citiranje

Fala, Loretta. "Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer." Am Health Drug Benefits 2016.